





Approximately 1 in 16
people will be diagnosed
with a rare disease at
some point during their
lifetime

We focus exclusively on rare diseases and uncommon cancers

2 3

COMRADIS EXCELS

IN THREE CORE AREAS

COMMUNICATION

Clear and compelling clinical evidence, data and stories to guide practice and inform decision-making



COMMERCIALIZATION

Supporting every stage of the development of new therapies. From opportunity assessment, clinical programme design and access strategies, through to global launch support



COMMUNITIES

Facilitating collaboration between patients, healthcare professionals and decision-makers to enhance understanding and expand access



With more than 50 years of experience in rare diseases between us, we specialize in identifying the strategies that provide the greatest value to each client. By applying our expertise to activities that have the greatest impact, we help our clients to accelerate towards improved patient care

FOCUS

Ve work exclusively on rare disease and uncommon cancers, servin pharmaceutical companies, rar disease specialists and patier advocacy organization



EXPERIENCE AND EXPERTISE

Bringing talent and knowledge, our team include healthcare communications specialists and consultant with experience in clinical development, marketing regulatory affairs, forecasting, commercialization, valu communications, medical affairs and patient advocace.



CREATIVITY AND CURIOSITY

We're not satisfied to adhere to the status quo. We use our experience and expertise to tackle challenges unique to each therapy area and look for the most effective ways to provide value to our clients and promote improved patient care. We continually review and refine our approach to reflect new ideas and ensure the highest of quality



GLOBAL REACH

With offices in Asia and the Pacific, the Middle East Europe and North America, Comradis provides loca nsights, knowledge and reach across multiple markets



CASE STUDIES

Comradis is a full-service healthcare communications and consulting agency, working exclusively on projects related to rare diseases and uncommon cancers. With capacity to support clients on both ad-hoc assignments and complex strategic programmes, Comradis has expertise in a broad range of communication, commercialization and communityfocused activities

Facilitating the development of a medical affairs strategy for a rare ophthalmic condition by mapping local and regional patient journeys, identifying blockages that delay diagnosis and restrict access to treatment, and providing recommendations for how they may be overcome

<u>....l</u>

Targeting medical education activities in Asia by mapping local real-life clinical practice for a rare metabolic disease against international clinical guidelines Working in partnership with several global pharmaceutical companies and Rare Cancers Australia to survey patient groups across Australasia, and Asia to understand challenges in building organizations, accessing health policymakers, fundraising and engaging with research. Surveys were conducted in 17 countries and translated into 7 different languages

and treatment of a rare cancer by hosting more than 250 clinicians in an interactive forum at a major international congress

Sharing best practice in the diagnosis

Enabling a client to target clinicians likely to diagnose a rare bone disorder by identifying and profiling more than 1200 relevant healthcare professionals across Europe, North America and Latin America



Helping local brand teams to secure reimbursement for a novel treatment for a rare kidney disease by profiling local payers across Asia, Europe, North America and Latin America, and providing advice on local requirements for health technology assessments

Engaging with expert clinicians from North America and Europe to develop new international guidelines for clinical trial design for neuronopathic rare diseases



Facilitating the launch of a new treatment across Asia, the Middle East, Europe and Latin America, by working with local affiliates to develop meaningful local plans to align with the global strategy

Developing an interactive iPad application to explain findings from a complex cost-effectiveness model for a novel therapy for a rare kidney disease



Providing advice on regulatory strategy and preparing applications for orphan drug designation and PRIME designation with the European Medicines Agency for US-based companies looking to enter the European market

If you would like to have an informal discussion about how Comradis can expedite your route to improved patient care, please get in touch



Rare disease expertise

Developing partnerships with clients, patients, caregivers, advocates and clinicians to secure a better future for families affected by rare diseases and uncommon cancer

For further information, please contact us team@comradis.biz www.comradis.biz

Comradis is part of AMICULUM, an independent global healthcare communications and learning business established in 2001. AMICULUM combines small agency entrepreneurial flair and flexibility with the experience and ability to deliver complex integrated programmes anywhere in the world. AMICULUM is a family of seven healthcare agency brands, each with its own distinctive character and area of expertise